Prevalence and real-world effectiveness of popular smoking cessation aids in England: a population-based study
Jackson, S. E.; Brown, J.; Buss, V.; Shahab, L.
Show abstract
ImportanceA wide range of medications, non-combustible nicotine products, behavioural support, and alternative treatments are available in England to help people stop smoking. Understanding their effectiveness in the real world can support informed decision-making. ObjectivesTo provide up-to-date estimates of the prevalence and real-world effectiveness of different smoking cessation aids and explore moderation of effectiveness by socioeconomic position. DesignPopulation-based survey, 2006-2024. SettingEngland. Participants25,094 adults ([≥]16y) who reported having tried to quit smoking in the past year. Main outcomes and measuresThe outcome variable was self-reported continuous abstinence from the start of the most recent quit attempt up to the time of survey. Independent variables were use (yes/no) of the following aids in the most recent attempt: nicotine replacement therapy (NRT) obtained on prescription or over-the-counter; varenicline; bupropion; e-cigarettes; face-to-face behavioural support; telephone support; written self-help materials; websites; smartphone apps; hypnotherapy; Allen Carrs Easyway method; heated tobacco products (HTPs); nicotine pouches. Covariates included sociodemographic characteristics and features of the quit attempt. ResultsWe analysed data from 25,094 participants (mean [SD] age = 38.7y [15.3]; 48.5% women). In 2023/24, the most used aids were e-cigarettes (40.2%) and over-the-counter NRT (17.3%); 40.8% of quit attempts were unaided. While e-cigarette use was associated with higher odds of abstinence after adjustment for use of other aids and covariates (OR=1.95 [1.74-2.17]), use of over-the-counter NRT was not (OR=1.03 [0.93-1.15]). Other aids positively associated with abstinence were websites (used by 4.6% in 2023/24; OR=1.43 [1.03-1.98]), prescription NRT (4.5%; OR=1.33 [1.12-1.58]), varenicline (1.1%; OR=1.80 [1.50-2.18]), and HTPs (0.7%; OR=2.37 [1.24-4.51]). Face-to-face behavioural support (used by 2.2% in 2023/24) was also associated with higher odds of abstinence among those from less advantaged (OR=1.59 [1.19-2.14]) but not more advantaged social grades (OR=0.91 [0.65-1.29]). There was not clear evidence of a benefit of any other aid, although some analyses were inconclusive. Conclusions and relevanceA range of effective smoking cessation aids are available in England, but many people try to quit using less effective forms of support or none at all. Quit success rates could be improved by encouraging people to use more effective methods.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Changes in vaping trends since the announcement of an impending ban on disposable vapes: a population study in Great Britain 96%
- Transitions from smoking to exclusive e-cigarette use, dual use, or stopping nicotine use in ALSPAC and their association with modifiable and sociodemographic factors 96%
- Moderators of changes in smoking, drinking, and quitting behaviour associated with the first Covid-19 lockdown in England 95%
Similar papers in this journal
- Trends in daily cigarette consumption among smokers: a population study in England, 2008-2023 96%
- Varenicline Versus Cytisine for Smoking Cessation in a Primary Care Setting: A Randomized Controlled Trial 95%
- What is the relationship between raising the minimum legal sales age of tobacco above 20 and cigarette smoking? A systematic review 94%
Similar papers in this journal
- E-cigarettes With Varenicline Versus Varenicline for Smoking Cessation: A Pragmatic Randomised Controlled Trial 98%
- Associations between e-cigarette use and e-cigarette flavors with cigarette smoking quit attempts and quit success: Evidence from a US large, nationally representative 2018-2019 survey 96%
- Effect of Electronic Nicotine Delivery Systems on Cigarette Abstinence in Smokers with no Plans to Quit: Exploratory Analysis of a Randomized Placebo-Controlled Trial 94%
Similar papers in this journal
- Associations between vaping and Covid-19: cross-sectional findings from the HEBECO study 95%
- Associations between reasons for vaping and current vaping and smoking status: Evidence from a UK based cohort 93%
- Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020 to 2023 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.